BLRX
BioLineRx·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
BLRX Profile
Biolinerx Ltd.
A late clinical-stage biopharmaceutical company focused on oncology
Biological Technology
--
07/25/2011
NASDAQ Stock Exchange
24
12-31
Depository Receipts (Ordinary Shares)
2 HaMa’ayan Street, Modi’in 7177871, Israel
Late-stage clinical-stage biopharmaceutical companies.
BioLineRx Ltd. Incorporated and commenced business in April 2003, it is a clinical-stage biopharmaceutical development company. The company is committed to identifying, licensing and developing drug candidates that have advantages over existing available treatments or that can address medical needs. The current development pipeline includes six clinical stage therapeutic candidates: BL -1040, a novel polymer solution for the prevention of ventricular remodeling after acute myocardial infarction, or AMI; BL -8040, a novel peptide for the treatment of acute myeloid leukemia (AML), stem cell mobilization and hematological indications; BL -7010, a novel polymer for the treatment of celiac disease; BL -5010, A customized, proprietary pen applicator containing a novel formulation of two acids is being developed in Europe as a medical device for non-surgical resection of benign skin lesions; BL-7040, an oligonucleotide for the treatment of inflammatory bowel disease, or IBD; and BL-8020, an oral drug for the treatment of hepatitis C virus (HCV) and viral indications, with a unique mechanism of action involving the inhibition of virus-induced autophagy in host cells.
